https://www.selleckchem.com/products/avelumab.html
Hepatitis B surface antigen (HBsAg) seroclearance is considered a realistic goal in patients with chronic hepatitis B (CH, known as "functional cure". However, it remains elusive whether nucleos(t)ide analogue (NUC)-induced HBsAg seroclearance, compared with spontaneous HBsAg seroclearance, differs in its association with favorable long-term clinical outcomes. A total of 1,972 CHB patients with confirmed HBsAg seroclearance at least two consecutive times, 6months apart, were retrospectively analyzed. The risks of hepatocellular carci
Like
Comment
Share
